Physician profile
Lance A Besner
NPI 1265433361
$17,372.84
in general payments reported to CMS, 2019-2025
18 companies · $3,237 in 2025
The $3,237 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,792 · 2020: $939 · 2021: $1,742 · 2022: $3,033 · 2023: $2,926 · 2024: $2,705 · 2025: $3,237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,867.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $3,884.87 | 2020-2025 | Caplyta |
| Abbvie INC. | $2,199.45 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $1,881.77 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $1,512.66 | 2019-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $1,391.54 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Vanda Pharmaceuticals INC. | $1,109.23 | 2019-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $1,084.27 | 2019-2025 | Lybalvi, Aristada |
| Takeda Pharmaceuticals U.S.A., INC. | $955.47 | 2019-2025 | Trintellix |
| Axsome Therapeutics, INC. | $905.52 | 2023-2025 | Auvelity |
| Allergan, INC. | $787.64 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $517.33 | 2019-2025 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $312.17 | 2019 | |
| Janssen Pharmaceuticals, INC | $287.80 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $171.44 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $159.20 | 2019-2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $124.90 | 2024 | Cobenfy |
| Almatica Pharma LLC | $68.69 | 2021-2022 | |
| Alfasigma USA, INC. | $18.89 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Besner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.